Page last updated: 2024-10-16

adenine and Hematologic Malignancies

adenine has been researched along with Hematologic Malignancies in 28 studies

Research Excerpts

ExcerptRelevanceReference
"We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis."4.95Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. ( Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ, 2017)
"This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations."2.87A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. ( Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J, 2018)
" Furthermore, the nanoformulations studied to increase ibrutinib bioavailability are reported."2.72Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. ( Brullo, C; Russo, E; Spallarossa, A; Tasso, B; Villa, C, 2021)
"Increased infections have been observed in patients taking ibrutinib."2.58Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. ( Pauff, JM; Satyanarayana, G; Talbott, M; Tillman, BF; Warner, JL, 2018)
"Overall, AF and bleeding are manageable clinical events in patients receiving IB, not requiring drug interruption in most cases."2.58Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. ( Boriani, G; Corradini, P; Cuneo, A; Falanga, A; Foà, R; Gaidano, G; Ghia, PP; Marasca, R; Martelli, M; Massaia, M; Mauro, FR; Minotti, G; Molica, S; Montillo, M; Pinto, A; Tedeschi, A; Vitolo, U; Zinzani, PL, 2018)
" phase I/II trials have been conducted to evaluate the dosing schedules and activity of this agent."2.58BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). ( He, W; Hu, H, 2018)
" However, BTKi have a range of drug-drug and drug-food interactions, which may alter drug efficacy and/or increase toxicity."1.56Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. ( Fancher, KM; Pappacena, JJ, 2020)
"Low-grade bleeding was more common in ibrutinib-treated than comparator-treated patients (35% and 15%), and early low-grade bleeding was not associated with MH."1.51Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. ( Bista, A; Boornazian, L; Brown, JR; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Cramer, P; Cymbalista, F; Dilhuydy, MS; Dreyling, M; Ewer, MS; Fraser, G; Ghia, P; Graef, T; Jaeger, U; Liu, EY; Mahler, M; Moslehi, J; O'Brien, SM; Reddy, V; Rule, S; Shanafelt, TD; Treon, S; Valentino, R; Vempati, R; Yang, H, 2019)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's20 (71.43)24.3611
2020's8 (28.57)2.80

Authors

AuthorsStudies
Egger, M1
Gornicec, M1
Wölfler, A1
Lembeck, AL1
Tinchon, C1
Maderdonner, M1
Prattes, J1
Kander, EM1
Zhao, Q1
Bhat, SA1
Hirsch, J1
Byrd, JC3
Ooka, L1
Wiczer, T2
Woyach, JA2
Awan, FT1
Rogers, KA2
Wang, TF1
Dickerson, T1
Waller, A1
Philippon, J1
Porter, K1
Haddad, D1
Guha, A1
Bhat, S1
Awan, F1
Addison, D1
Lewis, T1
Corcoran, DB1
Thurston, DE1
Giles, PJ1
Ashelford, K1
Walsby, EJ1
Fegan, CD1
Pepper, AGS1
Miraz Rahman, K1
Pepper, C1
Cordoba, R2
Fancher, KM1
Pappacena, JJ1
Danilov, AV1
Persky, DO1
Tazi, I1
Ciuculete, DC1
Popescu, RA1
Dan, GA1
Brullo, C1
Villa, C1
Tasso, B1
Russo, E1
Spallarossa, A1
Zhang, MY1
Zhu, GQ1
Zheng, JN1
Cheng, Z1
Van Poucke, S1
Shi, KQ1
Huang, HH1
Chen, FY1
Zheng, MH1
Schaffer, M1
Chaturvedi, S1
Davis, C1
Aquino, R1
Stepanchick, E1
Versele, M1
Liu, Y1
Yang, J1
Lu, R1
Balasubramanian, S1
Garside, J1
Healy, N1
Besson, H1
Hermans, R1
MacDougall, F1
Lestelle, D1
Diels, J1
Iraqi, W1
Chamilos, G1
Lionakis, MS1
Kontoyiannis, DP1
Snijder, B1
Vladimer, GI1
Krall, N1
Miura, K1
Schmolke, AS1
Kornauth, C1
Lopez de la Fuente, O1
Choi, HS1
van der Kouwe, E1
Gültekin, S1
Kazianka, L1
Bigenzahn, JW1
Hoermann, G1
Prutsch, N1
Merkel, O1
Ringler, A1
Sabler, M1
Jeryczynski, G1
Mayerhoefer, ME1
Simonitsch-Klupp, I1
Ocko, K1
Felberbauer, F1
Müllauer, L1
Prager, GW1
Korkmaz, B1
Kenner, L1
Sperr, WR1
Kralovics, R1
Gisslinger, H1
Valent, P1
Kubicek, S1
Jäger, U1
Staber, PB1
Superti-Furga, G1
Tillman, BF1
Pauff, JM1
Satyanarayana, G1
Talbott, M1
Warner, JL1
Hammond, SP1
Chen, K1
Pandit, A1
Davids, MS1
Issa, NC1
Marty, FM1
Boriani, G1
Corradini, P1
Cuneo, A1
Falanga, A1
Foà, R1
Gaidano, G1
Ghia, PP1
Martelli, M1
Marasca, R1
Massaia, M1
Mauro, FR1
Minotti, G1
Molica, S1
Montillo, M1
Pinto, A1
Tedeschi, A1
Vitolo, U1
Zinzani, PL1
He, W1
Hu, H1
de Jong, J1
Hellemans, P1
De Wilde, S1
Patricia, D1
Masterson, T1
Manikhas, G1
Myasnikov, A1
Osmanov, D1
Panizo, C1
de Zwart, L1
Snoeys, J1
Chauhan, V1
Jiao, J1
Sukbuntherng, J1
Ouellet, D1
Nastoupil, LJ1
Prasad, V1
Flowers, CR1
Mock, J1
Kunk, PR1
Palkimas, S1
Sen, JM1
Devitt, M1
Horton, B1
Portell, CA1
Williams, ME1
Maitland, H1
Brown, JR1
Moslehi, J1
Ewer, MS1
O'Brien, SM1
Ghia, P1
Cymbalista, F1
Shanafelt, TD1
Fraser, G1
Rule, S1
Coutre, SE1
Dilhuydy, MS1
Cramer, P1
Jaeger, U1
Dreyling, M1
Treon, S1
Liu, EY1
Chang, S1
Bista, A1
Vempati, R1
Boornazian, L1
Valentino, R1
Reddy, V1
Mahler, M1
Yang, H1
Graef, T1
Burger, JA1
Ezad, S1
Khan, AA1
Cheema, H1
Ashraf, A1
Ngo, DTM1
Sverdlov, AL1
Collins, NJ1
Prins, RC1
Burke, RT1
Tyner, JW1
Druker, BJ1
Loriaux, MM1
Spurgeon, SE1
Liu, N1
Hoogendoorn, S1
van de Kar, B1
Kaptein, A1
Barf, T1
Driessen, C1
Filippov, DV1
van der Marel, GA1
van der Stelt, M1
Overkleeft, HS1
Smithson, CR1
Schneider, SM1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology[NCT04470947]150 participants (Anticipated)Observational [Patient Registry]2020-06-10Recruiting
Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial[NCT06138990]82 participants (Anticipated)Interventional2024-02-01Not yet recruiting
A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients[NCT03096821]143 participants (Actual)Observational2015-09-30Completed
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]40 participants (Actual)Observational [Patient Registry]2018-12-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for adenine and Hematologic Malignancies

ArticleYear
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    British journal of haematology, 2021, Volume: 193, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a

2021
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
    International journal of molecular sciences, 2021, Jul-16, Volume: 22, Issue:14

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chemistry, Pharmaceutical; COVID-19 Drug Treatment; Dr

2021
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Expert review of anti-infective therapy, 2017, Volume: 15, Issue:5

    Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepa

2017
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
    European journal of haematology, 2018, Volume: 100, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth

2018
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
    Hematological oncology, 2018, Volume: 36, Issue:4

    Topics: Adenine; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Hema

2018
BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
    Oncology reports, 2018, Volume: 40, Issue:1

    Topics: Adenine; Apoptosis; Hematologic Neoplasms; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted The

2018
Ibrutinib: a new targeted therapy for hematologic cancers.
    Clinical journal of oncology nursing, 2015, Volume: 19, Issue:3

    Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; Hematologic Neoplasms;

2015

Trials

6 trials available for adenine and Hematologic Malignancies

ArticleYear
Hypertension and incident cardiovascular events following ibrutinib initiation.
    Blood, 2019, 11-28, Volume: 134, Issue:22

    Topics: Adenine; Aged; Antihypertensive Agents; Female; Heart Diseases; Hematologic Neoplasms; Humans; Hyper

2019
PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
    Journal of comparative effectiveness research, 2018, Volume: 7, Issue:1

    Topics: Adenine; Comparative Effectiveness Research; Data Collection; Databases, Factual; Hematologic Neopla

2018
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine;

2017
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Aged; Aged, 80 and over; Female; Follow-Up Studies; Hematologic Neoplasms; Hepatitis B; Hep

2018
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:12

    Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco

2018
Ibrutinib-related atrial fibrillation: A single center Australian experience.
    Asia-Pacific journal of clinical oncology, 2019, Volume: 15, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Australia; Female; Hematologic Neoplasms; Hos

2019

Other Studies

15 other studies available for adenine and Hematologic Malignancies

ArticleYear
Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria.
    Medical mycology, 2022, Sep-15, Volume: 60, Issue:9

    Topics: Adenine; Animals; Antifungal Agents; Austria; Hematologic Neoplasms; Humans; Incidence; Invasive Fun

2022
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.
    British journal of haematology, 2019, Volume: 187, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Middl

2019
Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17 Suppl 1, Issue:1

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chloramb

2019
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
    Haematologica, 2021, 04-01, Volume: 106, Issue:4

    Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocyt

2021
Bringing hospital care closer to patients amidst COVID-19.
    The Lancet. Haematology, 2020, Volume: 7, Issue:9

    Topics: Adenine; Betacoronavirus; Checklist; Coronavirus Infections; COVID-19; Hematologic Neoplasms; Humans

2020
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbid

2020
[Antineoplasic drug repurposing in hematology for COVID-19 treatment].
    Bulletin du cancer, 2021, Volume: 108, Issue:4

    Topics: Adenine; Aniline Compounds; COVID-19 Drug Treatment; Drug Repositioning; Hematologic Neoplasms; Huma

2021
Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2021, Sep-01, Volume: 59, Issue:3

    Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Hematologic Neoplasms; Hemorrha

2021
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera

2018
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 01-06, Volume: 66, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Female; Fungi; Hematologic Neoplasms; Humans; Immunosuppressive Ag

2018
The need to assess financial adverse events.
    The Lancet. Haematology, 2018, Volume: 5, Issue:11

    Topics: Adenine; Child; Costs and Cost Analysis; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperidin

2018
Risk of Major Bleeding with Ibrutinib.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hematologic Neop

2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
    British journal of haematology, 2019, Volume: 184, Issue:4

    Topics: Adenine; Aged; Female; Hematologic Neoplasms; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pipe

2019
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Imm

2013
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
    Organic & biomolecular chemistry, 2015, May-14, Volume: 13, Issue:18

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Hematologic Neoplasms; Humans; Molecular Probes; Nethe

2015